Medistim

Earnings Release • Oct 24, 2017

3rd quarter results 2017 for Medistim ASA

3rd quarter results 2017 for Medistim ASA

Medistim delivers record sales and result for a quarter. Sales ended

at MNOK 75.7 for the quarter (MNOK 67.9), an 11.4 % growth. Sales as

of September increased by 9.3 % and ended at MOK 219.2 (MNOK 200.6).

The revenue growth is driven by sales of own products and currency

neutral growth was 12.5 % for the quarter and 11.5 % YTD.

Operating profit (EBIT) for the quarter ended at MNOK 19.4 (MNOK

15.9). Operating profit as of September ended at MNOK 49.1 (MNOK

46.6). Continued strong growth in USA with a currency neutral growth

of 17.8 %. Preliminary data from the REQUEST study supports

Medistim's hypothesis; The combination of flow measurements and

ultrasound imaging during cardiac bypass surgery improve surgical

outcome. Production capacity has improved in the 3 quarter and the

back order situation is estimated to be solved by year end.